Nanobiotix (NANO) Q1 2026 earnings summary

Executive summary

• Advanced clinical programs for JNJ-1900 (NBTXR3) in collaboration with J&J, with promising efficacy and safety data in unresectable Stage 3 NSCLC and protocol amendments to accelerate pivotal studies.

• Completed a follow-on offering in May 2026, raising €86.1 million to accelerate platform development.

• Presented new clinical and preclinical data for JNJ-1900 (NBTXR3) and Nanoprimer platforms at major oncology conferences.

• FDA accepted a protocol amendment for the pivotal NANORAY-312 study, expediting final analysis.

Financial highlights

• Cash and cash equivalents totaled €42.1 million as of March 31, 2026.

• Recent follow-on offering raised €86.1 million in gross proceeds, including pre-funded warrants.

• Current cash position and proceeds from the offering are expected to fund operations into 2029 based on projected cash burn rate.

Outlook and guidance

• Cash runway projected to support operations into 2029, assuming current burn rate and use of proceeds from the recent offering.